Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/12465
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gu, X H | en |
dc.contributor.author | Liu, J J | en |
dc.contributor.author | Dillon, J S | en |
dc.contributor.author | Nayler, W G | en |
dc.date.accessioned | 2015-05-16T02:10:00Z | |
dc.date.available | 2015-05-16T02:10:00Z | |
dc.date.issued | 1989-02-01 | en |
dc.identifier.citation | British Journal of Pharmacology; 96(2): 262-4 | en |
dc.identifier.govdoc | 2538185 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/12465 | en |
dc.description.abstract | The effect of endothelin, a potent vasoconstrictor polypeptide, on three types of calcium antagonist binding sites was examined, in rat cardiac membrane fragments. Endothelin 10 nM affected neither the affinity nor density of dihydropyridine binding sites. At concentrations of 10(-12)-10(-7) M, endothelin failed to displace bound (+)-[3H]-PN 200/110, (-)-[3H]-D888 and (+)-cis-[3H]-diltiazem. These results suggest that the calcium antagonist binding sites associated with L-type calcium channels are not the primary site of action of endothelin. | en |
dc.language.iso | en | en |
dc.subject.other | Animals | en |
dc.subject.other | Binding, Competitive | en |
dc.subject.other | Calcium Channel Blockers.metabolism | en |
dc.subject.other | Calcium Channels | en |
dc.subject.other | Diltiazem.metabolism | en |
dc.subject.other | Endothelins | en |
dc.subject.other | Female | en |
dc.subject.other | In Vitro Techniques | en |
dc.subject.other | Isradipine | en |
dc.subject.other | Oxadiazoles.metabolism | en |
dc.subject.other | Peptides.metabolism.pharmacology | en |
dc.subject.other | Rats | en |
dc.subject.other | Rats, Inbred Strains | en |
dc.subject.other | Receptors, Nicotinic.drug effects | en |
dc.subject.other | Verapamil.analogs & derivatives.metabolism | en |
dc.title | The failure of endothelin to displace bound, radioactively-labelled, calcium antagonists (PN 200/110, D888 and diltiazem). | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | British journal of pharmacology | en |
dc.identifier.affiliation | Department of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria. | en |
dc.description.pages | 262-4 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/2538185 | en |
dc.type.austin | Journal Article | en |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.